Venture
MapLight Therapeutics, Inc.
Latest Form D 2025-07-28- CIK 1770069
- State CA
- Biotechnology
- 6 Form D offerings since 2019-03-08
- Total sold
- $356M
- across 6 offerings
- Rounds
- 6
- Form D offerings since 2019-03-08
- Latest round
- $188M
- 2025-07-28 · 021-552922
- Investors
- 19
- on the latest round
Connected
named in its Form D filingsOfferings · since 2019-03-086 Form D offeringsExemptions506(b)People · Item 3Christopher A Kroeger + 12 moreInvestors · dashboardInferred investors
MapLight Therapeutics, Inc.CIK 1770069
Round timeline
amount sold · by first filed2025-07-28 · $188M
- 2019-03-08$5M021-334440
- 2019-09-04$16M021-347993
- 2021-03-10$30M021-391790
- 2022-11-10$12M021-464468
- 2023-07-19$105M021-487390
- 2025-07-28$188M021-552922
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($188M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-552922 | First filed2025-07-28 | Latest2025-07-28 | Sought$372M | Sold$188M | Investors19 | Exemptions506(b) |
| 021-487390 | First filed2023-07-19 | Latest2023-11-03 | Sought$225M | Sold$105M | Investors12 | Exemptions506(b) |
| 021-464468 | First filed2022-11-10 | Latest2022-11-10 | Sought$12M | Sold$12M | Investors1 | Exemptions506(b) |
| 021-391790 | First filed2021-03-10 | Latest2021-03-10 | Sought$60M | Sold$30M | Investors2 | Exemptions506(b) |
| 021-347993 | First filed2019-09-04 | Latest2019-09-04 | Sought$16M | Sold$16M | Investors2 | Exemptions506(b) |
| 021-334440 | First filed2019-03-08 | Latest2019-03-22 | Sought$5M | Sold$5M | Investors2 | Exemptions506(b) |
Who backs MapLight Therapeutics, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-07-28
| Name | Relationship |
|---|---|
| Christopher A Kroeger | RelationshipExecutive Officer, Director |
| George Pavlov | RelationshipDirector |
| Timothy Garnett | RelationshipDirector |
| James Lillie | RelationshipExecutive Officer |
| Peter Bisgaard | RelationshipDirector |
| Jonathan Gillis | RelationshipExecutive Officer |
| Vishwas Setia | RelationshipExecutive Officer |
| Jim Trenkle | RelationshipDirector |
| Maria Walker | RelationshipDirector |
| Kristopher Hanson | RelationshipExecutive Officer |
| Nanna Luneborg | RelationshipDirector |
| Erin Foff | RelationshipExecutive Officer |
| Anatol Kreitzer | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2019-03-08
- Latest filing
- 2025-07-28
Who backs MapLight Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗